Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMX103 1.5% for papulopustular rosacea
CTR20212555Phase 3Terminated
- Sponsor
- Foamix Pharmaceuticals Ltd.
- Start
- Oct 2021
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in papulopustular rosacea comparing FMX103 1.5% foam with Vehicle foam (2 arms). Primary endpoints: Change from baseline in inflammatory lesion count at week 12 and Investigator Global Assessment (IGA) treatment success at week 12. Started Oct 2021; status: terminated.
02
Drugs
zilxi
03
Conditions
papulopustular rosacea
Beyond the preview
Go deeper on CTR20212555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212555.